Faculty profile

Michael Brundage

ResearcherCancer Care and EpidemiologyQueen's University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.

Michael Brundage

Researcher

Cancer Care and Epidemiology

Queen's University

Kingston, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
36 publications in the last five years, latest in 2026.
Senior (last) author on 8 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

122

Publications

1,578

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Advanced Cancer Discrete Choice Experiement Overall Survival Patient Values Progression-Free Survival Systemic Therapy Trade-Off Methods

Latest papers

Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial
Journal of Clinical Oncology · 2026
From framework to practice: applying the proteus-practice framework to learn lessons for integrating PROs in clinical care.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.
Endocrine oncology (Bristol, England) · 2026

All 122 publications

Latest funding

TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
CIHR · 2024 · Co-investigator
$2,487,015
Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
CIHR · 2022 · Co-investigator
$4,475,254
Understanding how cancer patients value progression-free survival
CIHR · 2019 · Nominated PI
$175,951

All 7 grants and awards

122 publications.

Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial

Chan KKW, Chu RWK, Cheung MC, Courneya KS, O'Callaghan CJ, Vardy JL, Gill S, Friedenreich C, Wong RKS, Dhillon HM

Journal of Clinical Oncology20261 citations

DOI: 10.1200/jco-26-00765

From framework to practice: applying the proteus-practice framework to learn lessons for integrating PROs in clinical care.

Schuster ALR, Snyder C, Haverman L, Cracchiolo JR, Schougaard LMV, Cizik AM, Sandhu ATS, Brundage M, Crossnohere NL

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026

DOI: 10.1007/s11136-026-04297-7 PMID: 42295503

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Gorman M, Usmani N, Pollak MN, Ghosh S, Elangovan A, Kim J, Thoms J, Bouchard M, Peacock M, Wang Y, Fleshner NE, Campbell H, Vigneault E, Vincent F, So A, Cury FL, Quon HC, Carlson RG, Lambert C, Klotz L, Chi K, Brundage M, Courneya KS, Eigl BJ

Endocrine oncology (Bristol, England)2026

DOI: 10.1530/eo-25-0114 PMID: 42395839

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

Courneya KS, Vardy JL, O'Callaghan CJ, Gill S, Friedenreich CM, Wong RKS, Dhillon HM, Coyle V, Chua NS, Jonker DJ

New England Journal of Medicine2025375 citations

DOI: 10.1056/nejmoa2502760

Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer

Tannock IF, Pe ML, Booth CM, Brundage M, Cherny NI, Coens C, Eisenhauer EA, Geissler J, Giesinger JM, Gyawali B

The Lancet Oncology202517 citations

DOI: 10.1016/s1470-2045(25)00288-8

SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.

Amdal CD, Falk RS, Alanya A, Schlichting M, Roychoudhury S, Bhatnagar V, Wintner LM, Regnault A, Ingelgård A, Coens C, le Cessie S, Holzner B, Chang J, Taphoorn M, Cislo P, Giesinger JM, Cappelleri JC, Pawar V, Ten Seldam S, Papadopoulos EJ, Calvert MJ, Joseph KL, Bottomley A, Griebsch I, Arraras JI, Astrup GL, Basch E, Belančić A, Brundage M, Campbell A, Rerhou Rantell K, Cocks K, Cherny N, Eremenco S, Ferrer M, Fiero MH, Gerlinger C, Goetghebeur E, Grouven U, Lauer A, Aiyegbusi OL, Machingura A, Mizusawa J, Molenberghs G, Aa Petersen M, Reijneveld JC, Ringash J, Rumpold G, Rutherford C, Quinten C, Sail K, Sasseville M, Sauerbrei W, Schiel A, Smith AW, Snyder C, Velikova G, Wang XS, Bjordal K, Pe M, SISAQOL-IMI Consortium

The Lancet. Oncology2025

DOI: 10.1016/s1470-2045(25)00520-0 PMID: 41308689

Reply by Authors.

Eigl BJ, Elangovan A, Ghosh S, Kim JO, Thoms J, Bouchard M, Peacock M, Fleshner N, Campbell H, Vigneault E, Vincent F, So A, Cury F, Quon H, Carlson R, Lambert C, Klotz L, Chi K, Brundage M, Pollak M, Rebane L, Chiu L, Courneya KS, Usmani N

The Journal of urology2025

DOI: 10.1097/ju.0000000000004731 PMID: 40928018

Patient-reported outcome measures add value as clinical trial endpoints.

Crossnohere NL, Schuster ALR, Bruckel J, Chen RC, Cizik AM, Cruz Rivera S, Muth C, Nelsen L, Kyte D, Wu AW, Thorner E, Snyder C, Brundage M

Nature medicine2025Senior author

DOI: 10.1038/s41591-025-03906-1 PMID: 40855193

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.

The Journal of urology2025

DOI: 10.1097/ju.0000000000004695 PMID: 40711960

A Framework to Promote Implementation of Patient-Reported Outcomes in Institutions Caring for Vulnerable and Underserved Cancer Populations.

Schuster ALR, Crossnohere NL, Boakye EA, Angove R, Baldwin B, Barreto EA, Chen RC, Gillespie TW, Hamilton B, McCleary NJ, Karmo M, Kaufmann T, Lee W, Mehta V, Meyer L, Mittal K, Owens L, Peterson R, Pusic A, Rainey AM, Richardson A, Shapiro L, Sibbitt B, Smith C, Vargo M, Vickers A, Brundage M, Snyder C

The patient2025

DOI: 10.1007/s40271-024-00703-9 PMID: 38909128

Something wrong or missing on this profile? Suggest a correction

Michael Brundage

Research

Latest papers

Latest funding

Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial

From framework to practice: applying the proteus-practice framework to learn lessons for integrating PROs in clinical care.

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer

SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.

Reply by Authors.

Patient-reported outcome measures add value as clinical trial endpoints.

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.

A Framework to Promote Implementation of Patient-Reported Outcomes in Institutions Caring for Vulnerable and Underserved Cancer Populations.

TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.

Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)

Understanding how cancer patients value progression-free survival

Real world outcomes of novel targeted agents for the treatment of metastatic HER-2 positive breast cancer in Ontario: A population-based study

Randomized Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low Risk Cervical Cancer Defined as Lesions Measuring Less than 2 cm with Less than 50% Stromal Invasion

Knowledge to Action: Developing and Implementing a CONSORT Extension for HRQL Reporting Standards

A National "Patterns of Care" Study in Prostate Cancer Radiation Therapy: Development and Use of Quality Indicators

Frequent collaborators

Ralph Meyer

Joda Kuk

Dongsheng Tu

Eric Vigneault

Christopher Booth

Michael Milosevic

Amanda Caissie

Jacqueline Galica

Raimond Wong

Jennifer Croke

Arjun Sahgal

Alan So

Michael Peacock

Neil Fleshner

Nawaid Usmani

Kim Chi

Meredith Giuliani

Andrew Robinson

Jackie Bender

Jessica Chan

Marc Gaudet

Tony Panzarella

Yingwei Peng

Feng Xie

Marc Kerba

Lehana Thabane

Michael Pollak

Gordon Guyatt

Neera Bhatnagar

An-Wen Chan

Michael Mckenzie

Doris Howell

Glenn Bauman

Juanita Crook

Fidel Rubagumya

Alejandro Berlin

Rashid Dar

Scott Tyldesley

Colleen Webber

Harriet Richardson